Altogether, our in vivo studies in multiple xenograft settings suggest that CXCR4 total protein loss, regardless of its surface expression, result in compromised tumor growth, and chemotherapeutic drug paclitaxel can be even more effective to further sensitize these tumors under this condition. The gene discussed is CXCR4; the disease is neoplasm.